These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30169978)

  • 1. Clinical translation of immunoliposomes for cancer therapy: recent perspectives.
    Wang D; Sun Y; Liu Y; Meng F; Lee RJ
    Expert Opin Drug Deliv; 2018 Sep; 15(9):893-903. PubMed ID: 30169978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions of liposome- and immunoliposome-based cancer therapeutics.
    Park JW; Benz CC; Martin FJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
    Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
    Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface Ligand Valency and Immunoliposome Binding: when More Is Not Always Better.
    Li H; Di J; Peng B; Xu Y; Zhang N
    Pharm Res; 2021 Sep; 38(9):1593-1600. PubMed ID: 34463936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
    Xu L; Huang CC; Huang W; Tang WH; Rait A; Yin YZ; Cruz I; Xiang LM; Pirollo KF; Chang EH
    Mol Cancer Ther; 2002 Mar; 1(5):337-46. PubMed ID: 12489850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone-Fused Enediyne.
    Feng X; Wen Z; Zhu X; Yan X; Duan Y; Huang Y
    Adv Sci (Weinh); 2024 May; 11(17):e2307865. PubMed ID: 38355309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoliposomes for Targeted Delivery of an Antifibrotic Drug.
    Schuster L; Seifert O; Vollmer S; Kontermann RE; Schlosshauer B; Hartmann H
    Mol Pharm; 2015 Sep; 12(9):3146-57. PubMed ID: 26181293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
    Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
    Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-HER2 immunoliposomes for targeted therapy of human tumors.
    Park JW; Hong K; Kirpotin DB; Meyer O; Papahadjopoulos D; Benz CC
    Cancer Lett; 1997 Oct; 118(2):153-60. PubMed ID: 9459205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-labeled liposomes for CT imaging of atherosclerotic plaques: in vitro investigation of an anti-ICAM antibody-labeled liposome containing iohexol for molecular imaging of atherosclerotic plaques via computed tomography.
    Danila D; Partha R; Elrod DB; Lackey M; Casscells SW; Conyers JL
    Tex Heart Inst J; 2009; 36(5):393-403. PubMed ID: 19876414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and
    Hua S
    J Liposome Res; 2019 Dec; 29(4):357-367. PubMed ID: 30526169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
    Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
    Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
    Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
    Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles.
    Santos EDS; Nogueira KAB; Fernandes LCC; Martins JRP; Reis AVF; Neto JBV; Júnior IJDS; Pessoa C; Petrilli R; Eloy JO
    Int J Pharm; 2021 Jan; 592():120082. PubMed ID: 33188892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-immunoliposome.
    Maruyama K
    Biosci Rep; 2002 Apr; 22(2):251-66. PubMed ID: 12428903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.